Floatz logo

Sacubitril Valsartan

Breast Neoplasm

Silesian Centre for Heart DiseasesSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

174 Active assets in the Breast Neoplasm cohort.

Asset / SponsorPhaseRating
Letrozole
Fujian Cancer Hospital
Phase 4BB
Adriamycin
Merck Sharp & Dohme LLC
Phase 4BB
Tamoxifen
Eli Lilly and Company
Phase 3BB
Exemestane
Fujian Cancer Hospital
Phase 4BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Sacubitril Valsartan is also rated in:

chemotherapy-induced hypertensionActive
BB
Indicative · Phase 4
65 / 100
View asset →
breast disorderActive
BB
Indicative · Phase 4
65 / 100
View asset →
secondary malignant neoplasmActive
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →